Send to

Choose Destination
See comment in PubMed Commons below
Bull NYU Hosp Jt Dis. 2006;64(1-2):72-6.

Update on treatment of arthritis in children: new treatments, new goals.

Author information

Children's Hospital Medical Center, Location E, Room 2-129, 3333 Burnet Avenue, Cincinnati, Ohio 45229, USA.


Although improved in recent years, the outcome for children who have juvenile idiopathic arthritis (JIA) is still less than ideal. Between 25% and 70% of children with JIA will still have active arthritis 10 years after disease onset, and over 40% will enter adulthood with active arthritis. Based on older publications, the fatality rate for JIA is 4- to 14-fold greater than an age- and sex-matched healthy population, and up to 39% of patients are significantly incapacitated, either wheelchair-bound or bedridden (Steinbrocker Classes III or IV). The hope is that recent changes in treatment approaches will result in marked improvement in long-term functional outcomes, although this has yet to be proven. JIA-associated chronic uveitis has a high frequency of serious complications: 20% develop cataracts, 19% glaucoma, and 16% band keratopathy. The anti-TNF biologics have all been tested in children with polyarticular JIA in blinded, placebo-controlled clinical trials, with over 70% in each trial demonstrating response that has been sustained in longer term follow-up studies. In systemic JIA approximately 50% respond to anti-TNF agents, but in many the response is not sustained. Openlabel studies have shown promising results for biologic therapies that block interleukins 1 and 6 in systemic JIA.

[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bulletin of the NYU Hospital for Joint Diseases
    Loading ...
    Support Center